Non Hodgkin Lymphoma Nhl clinical trials

Explore recruiting non hodgkin lymphoma nhl clinical trials.

Recruiting non hodgkin lymphoma nhl studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Non Hodgkin Lymphoma Nhl trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Modular Phase I/II Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Efficacy of AZD4512 Monotherapy or in Combination With Other Anticancer Agent(s), in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) (Lumi-NHL)

Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

Germany

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)

Poland, France, Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Randomized, Multi-Center, Parallel, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFY® plus Standard Medical Treatment Compared to Placebo plus Standard Medical Treatment to Prevent Infections in Patients with Hypogammaglobulinemia and Recurrent or Severe Infections Associated with B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

Romania, Poland, Hungary, Bulgaria, Croatia

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Belgium, Germany, Czechia, Spain, Hungary, France +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB 3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Czechia, Romania, Austria, Italy, Ireland, Spain +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Non Hodgkin Lymphoma Nhl trials by city

Non Hodgkin Lymphoma Nhl in Toronto Non Hodgkin Lymphoma Nhl in Vancouver Non Hodgkin Lymphoma Nhl in Montreal Non Hodgkin Lymphoma Nhl in Calgary Non Hodgkin Lymphoma Nhl in Edmonton Non Hodgkin Lymphoma Nhl in Ottawa Non Hodgkin Lymphoma Nhl in Winnipeg Non Hodgkin Lymphoma Nhl in Quebec City Non Hodgkin Lymphoma Nhl in Hamilton Non Hodgkin Lymphoma Nhl in Kitchener Non Hodgkin Lymphoma Nhl in London Non Hodgkin Lymphoma Nhl in Halifax Non Hodgkin Lymphoma Nhl in New York Non Hodgkin Lymphoma Nhl in Los Angeles Non Hodgkin Lymphoma Nhl in Chicago Non Hodgkin Lymphoma Nhl in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease